Full Press Release Details
ABBOTT PARK, Ill., Sept. 17, 2013 /PRNewswire/ -- Abbott (NYSE: ABT ) announced today it has received CE Marking (Conformite Europeenne) in Europe for the FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System ™ . The new icon-driven system provides sleek design, visual glucose trend indicators and insulin logging – all delivered in a single device to support daily diabetes management.
According to the World Health Organization, the prevalence of diabetes is increasing in the European region. Approximately 10 percent of women and men aged 25 years and older in Europe are living with diabetes[i], which makes diabetes one of the most prevalent chronic conditions.
Features of Abbott's FreeStyle Optium Neo System include:
Abbott's FreeStyle Optium Neo System will be available throughout Europe in the coming weeks. Individuals with diabetes who are interested in the FreeStyle Optium Neo System should consult with their healthcare professional.
About Abbott Diabetes Care
Abbott Diabetes Care, based in Alameda, California , is a leader in developing, manufacturing and marketing glucose monitoring systems designed to help people better manage their diabetes. Additional information about Abbott Diabetes Care may be found at www.abbottdiabetescare.com .
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.
Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.
[i] World Health Organization. Accessed August 2013 . http://www.euro.who.int/en/what-we-do/health-topics/noncommunicable-diseases/diabetes/facts-and-figures